Literature DB >> 17074750

Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface.

Andreas O Weinzierl1, Claudia Lemmel, Oliver Schoor, Margret Müller, Tobias Krüger, Dorothee Wernet, Jörg Hennenlotter, Arnulf Stenzl, Karin Klingel, Hans-Georg Rammensee, Stefan Stevanovic.   

Abstract

The major histocompatibility complex (MHC) presents peptides derived from degraded cellular proteins to T-cells and is thus crucial for triggering specific immune responses against viral infections or cancer. Up to now, there has been no evidence for a correlation between levels of mRNA (the "transcriptome") and the density of MHC-peptide complexes (the "MHC ligandome") on cells. Because such dependences are of intrinsic importance for the detailed understanding of translation efficiency and protein turnover and thus for systems biology in general and for tumor immunotherapy in practical application, we quantitatively analyzed the levels of mRNA and corresponding MHC ligand densities in samples of renal cell carcinomas and their autologous normal kidney tissues. Relative quantification was carried out by gene chip analysis and by stable isotope peptide labeling, respectively. In comparing more than 270 pairs of gene expression and corresponding peptide presentation ratios, we demonstrate that there is no clear correlation (r = 0.32) between mRNA levels and corresponding MHC peptide levels in renal cell carcinoma. A significant number of peptides presented predominantly on tumor or normal tissue showed no or only minor changes in mRNA expression levels. In several cases, peptides could even be identified despite the virtual absence of the respective mRNA. Thus we conclude that a majority of epitopes from tumor-associated antigens will not be found in approaches based mainly on mRNA expression studies as mRNA expression reflects a distorted picture of the situation on the cell surface as visible for T-cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074750     DOI: 10.1074/mcp.M600310-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  55 in total

Review 1.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

2.  Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action.

Authors:  Avital Lev; Michael F Princiotta; Damian Zanker; Kazuyo Takeda; James S Gibbs; Chiharu Kumagai; Elizabeth Waffarn; Brian P Dolan; Anne Burgevin; Peter Van Endert; Weisan Chen; Jack R Bennink; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

Review 3.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

Review 4.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

5.  The viral transcription group determines the HLA class I cellular immune response against human respiratory syncytial virus.

Authors:  Carolina Johnstone; Elena Lorente; Alejandro Barriga; Eilon Barnea; Susana Infantes; François A Lemonnier; Chella S David; Arie Admon; Daniel López
Journal:  Mol Cell Proteomics       Date:  2015-01-29       Impact factor: 5.911

6.  The human leukocyte antigen-presented ligandome of B lymphocytes.

Authors:  Chopie Hassan; Michel G D Kester; Arnoud H de Ru; Pleun Hombrink; Jan Wouter Drijfhout; Harm Nijveen; Jack A M Leunissen; Mirjam H M Heemskerk; J H Frederik Falkenburg; Peter A van Veelen
Journal:  Mol Cell Proteomics       Date:  2013-03-12       Impact factor: 5.911

Review 7.  A second chance for telomerase reverse transcriptase in anticancer immunotherapy.

Authors:  Maurizio Zanetti
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

Review 8.  Tools to define the melanoma-associated immunopeptidome.

Authors:  Eva Bräunlein; Angela M Krackhardt
Journal:  Immunology       Date:  2017-08-28       Impact factor: 7.397

9.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Authors:  C Berlin; D J Kowalewski; H Schuster; N Mirza; S Walz; M Handel; B Schmid-Horch; H R Salih; L Kanz; H-G Rammensee; S Stevanović; J S Stickel
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

10.  Systematic characterisation of cellular localisation and expression profiles of proteins containing MHC ligands.

Authors:  Agnieszka S Juncker; Mette V Larsen; Nils Weinhold; Morten Nielsen; Søren Brunak; Ole Lund
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.